Opioid Use Linked to Risk of Invasive Pneumococcal Disease

Share this content:
Opioid Use Linked to Risk of Invasive Pneumococcal Disease
Opioid Use Linked to Risk of Invasive Pneumococcal Disease

MONDAY, Feb. 12, 2018 (HealthDay News) -- Opioid use is associated with elevated risk of invasive pneumococcal disease (IPD), especially for long-acting, high-potency, and high-dose opioids, according to a study published online Feb. 13 in the Annals of Internal Medicine.

Andrew D. Wiese, Ph.D., from the Vanderbilt University Medical Center in Nashville, Tenn., and colleagues conducted a nested case-control study to examine whether prescription opioid use is an independent risk factor for IPD. A total of 1,233 case patients with IPD aged 5 years and older were matched to 24,399 control participants based on date of diagnosis, age, and county of residence.

The researchers found that persons in the case group had increased odds of being current opioid users compared with control participants (adjusted odds ratio (aOR), 1.62). The correlations were strongest for long-acting opioids (aOR, 1.87), high-potency opioids (aOR, 1.72), or use at high doses (50 to 90 morphine mg equivalents (MME)/day: aOR, 1.71; ≥90 MME/day: aOR, 1.75). When the IPD risk score was taken into account and when pneumonia and non-pneumonia IPD were analyzed separately, the results were consistent

"Opioid use is associated with an increased risk for IPD and represents a novel risk factor for these diseases," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »